Flagship unveils gene therapy startup Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 21 April, 2026

Hear from commercial leaders at Genentech, Pfizer, UCB, Denali, Catalyst, and other biopharma companies on patient-centricity in 2026. sponsored by Courier Health

presented by This Founder Could­n't Find His Own Clin­i­cal Tri­al. Now He's En­rolling Hun­dreds of Pa­tients for Phar­ma's Biggest Names

news Flagship’s latest startup aims to solve gene therapy’s thorniest technical challenge Soleno sold at a discount to Neurocrine due to dwindling European prospects Novartis has its anticoagulant back. Now it's cutting two programs

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA Trump, FDA plan to fast-track psychedelic drug access One of Kelonia's key investors will clear a 45-fold return on startup's sale to Lilly •  Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategy Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment

in case you missed it 1. Three gene therapy pioneers just won the Breakthrough Prize. This is their story 2. Gilead declines another Arcus option after Phase 3 TIGIT fail 3. KRAS drugmakers take another, better swing at lung cancer 4. News Briefing Merck partner reveals bispecific data; Biogen pays $100M for antibody rights 5.